Comparison
Selank vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
129954-34-3
2023788-19-2
Molecular weight
751.85 g/mol
4813 g/mol
Half-life
0.3 h
116 h
Sequence
Thr-Lys-Pro-Arg-Pro-Gly-ProYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
3
of which in humans
2
3
Effects recorded
3
4
Open conflicts
0
0
Documented adverse events
1
2